LEO Pharma AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
53
About the Report
About the Report
Summary
LEO Pharma A/S (LEO Pharma), a subsidiary of LEO Foundation is a research-based pharmaceutical company. It discovers, develops, manufactures and commercializes pharmaceuticals in therapeutic areas dermatology and thrombosis. The company focuses on the treatment of diseases such as psoriasis, eczema, skin infections, actinic keratosis and non-melanoma skin cancer, besides thrombosis. It also manufactures and markets products for the treatment of diseases in the areas of cardiovascular, bacterial infections, coagulation, osteoporosis and renal care. LEO Pharma markets its products worldwide and has presence in countries across Europe, the Middle East, Africa, Asia, North America, Central America, South America and Oceania. LEO Pharma is headquartered in Ballerup, Denmark.
LEO Pharma AS-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
LEO Pharma A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
LEO Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
LEO Pharma Acquires Prescription Dermatology Portfolio from Bayer 13
LEO Pharma Acquires Global Dermatology Portfolio of Astellas Pharma for USD724 Million 15
Partnerships 16
Leo Pharma Enters into Licensing Agreement with Klox Technologies 16
HitGen Enters into Research Agreement with LEO Pharma 17
LEO Pharma and LEO Pharma A/S Enter into Agreement with Kyowa Hakko Kirin 18
Klox Technologies and LEO Pharma to Form Joint Venture 19
MorphoSys Expands Agreement with LEO Pharma 20
LEO Pharma Enters into Agreement with Washington University School of Medicine 21
Leo Pharma Enters into Distribution Agreement with NeoPharm 22
arGEN-X Enters into Co-Development Agreement with Leo Pharma 23
Fidelta Enters into Drug Discovery Agreement with LEO Pharma 24
Leo Pharma Enters into Distribution and Co-Promotion Agreement with Kyowa Hakko Kirin 25
LEO Pharma And University of Queensland Enter Into Research Agreement For Skin Cancer 26
LEO Pharma Enters Into Research Agreement With 4SC For Inflammatory Skin Diseases 27
LEO Pharma To Enter Into Joint Venture With Charite To Form I2DEAL 28
Licensing Agreements 29
Zymeworks Enters into Research Collaboration and Licensing Agreement with LEO Pharma 29
LEO Pharma Enters into Licensing Agreement with JW Pharma 30
UTILITY therapeutics Enters into Licensing Agreement with LEO Pharma 31
LEO Pharma Enters into Licensing Agreement with AstraZeneca for Tralokinumab 32
LEO Pharma Enters Into Licensing Agreement With AstraZeneca For Brodalumab 33
Leo Pharma Enters into Licensing Agreement with Japan Tobacco for JTE-052 34
LEO Pharma Enters Into Licensing Agreement With Virobay For Psoriasis Drug 35
Equity Offering 36
LEO Pharma Invests in Novopyxis 36
Asset Transactions 37
Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 37
Amdipharm Mercury Completes Acquisition Of Fucithalmic, Ophthalmic Medicine, From LEO Pharma 39
LEO Pharma A/S-Key Competitors 40
LEO Pharma A/S-Key Employees 41
LEO Pharma A/S-Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 45
Financial Announcements 45
Mar 02, 2018: A record year for LEO Pharma 45
Apr 03, 2017: LEO Pharma 2016 result surpassed expectations 47
Corporate Communications 49
Aug 28, 2018: LEO Pharma appointed Olivier Bohuon as Board Director 49
May 28, 2018: LEO Pharma Names Christian Antoni as Senior Vice President for Global Development, R&D 50
Mar 20, 2018: LEO Pharma Appoints Rhonda Duffy To Lead Global Product Supply 51
Jun 23, 2017: LEO Pharma Appoints Chris Posner to Lead US Business 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53
List of Figure
List of Figures
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
LEO Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
LEO Pharma A/S, Pharmaceuticals & Healthcare, Key Facts, 2017 2
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
LEO Pharma A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
LEO Pharma A/S, Deals By Therapy Area, 2012 to YTD 2018 9
LEO Pharma A/S, Medical Devices Deals, 2012 to YTD 2018 10
LEO Pharma A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
LEO Pharma Acquires Prescription Dermatology Portfolio from Bayer 13
LEO Pharma Acquires Global Dermatology Portfolio of Astellas Pharma for USD724 Million 15
Leo Pharma Enters into Licensing Agreement with Klox Technologies 16
HitGen Enters into Research Agreement with LEO Pharma 17
LEO Pharma and LEO Pharma A/S Enter into Agreement with Kyowa Hakko Kirin 18
Klox Technologies and LEO Pharma to Form Joint Venture 19
MorphoSys Expands Agreement with LEO Pharma 20
LEO Pharma Enters into Agreement with Washington University School of Medicine 21
Leo Pharma Enters into Distribution Agreement with NeoPharm 22
arGEN-X Enters into Co-Development Agreement with Leo Pharma 23
Fidelta Enters into Drug Discovery Agreement with LEO Pharma 24
Leo Pharma Enters into Distribution and Co-Promotion Agreement with Kyowa Hakko Kirin 25
LEO Pharma And University of Queensland Enter Into Research Agreement For Skin Cancer 26
LEO Pharma Enters Into Research Agreement With 4SC For Inflammatory Skin Diseases 27
LEO Pharma To Enter Into Joint Venture With Charite To Form I2DEAL 28
Zymeworks Enters into Research Collaboration and Licensing Agreement with LEO Pharma 29
LEO Pharma Enters into Licensing Agreement with JW Pharma 30
UTILITY therapeutics Enters into Licensing Agreement with LEO Pharma 31
LEO Pharma Enters into Licensing Agreement with AstraZeneca for Tralokinumab 32
LEO Pharma Enters Into Licensing Agreement With AstraZeneca For Brodalumab 33
Leo Pharma Enters into Licensing Agreement with Japan Tobacco for JTE-052 34
LEO Pharma Enters Into Licensing Agreement With Virobay For Psoriasis Drug 35
LEO Pharma Invests in Novopyxis 36
Karo Pharma Acquires Product Portfolio of Ten Products from LEO Pharma for USD317.6 Million 37
Amdipharm Mercury Completes Acquisition Of Fucithalmic, Ophthalmic Medicine, From LEO Pharma 39
LEO Pharma A/S, Key Competitors 40
LEO Pharma A/S, Key Employees 41
LEO Pharma A/S, Subsidiaries 42
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.